Insider Selling: BeOne Medicines (NASDAQ:ONC) SVP Sells 590 Shares of Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 590 shares of BeOne Medicines stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $265.98, for a total transaction of $156,928.20. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Chan Henry Lee also recently made the following trade(s):

• On Thursday, June 11th, Chan Henry Lee sold 428 shares of BeOne Medicines stock. The stock was sold at an average price of $257.63, for a total transaction of $110,265.64.
• On Monday, June 8th, Chan Henry Lee sold 871 shares of BeOne Medicines stock. The shares were sold at an average price of $270.42, for a total transaction of $235,535.82.
• On Wednesday, May 13th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $310.72, for a total transaction of $103,159.04.
• On Wednesday, April 8th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $311.59, for a total transaction of $103,447.88.

BeOne Medicines Stock Up 2.8%

ONC stock traded up $7.47 during trading on Thursday, reaching $270.15. The stock had a trading volume of 367,884 shares, compared to its average volume of 260,552. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. The firm has a fifty day moving average price of $296.83 and a 200 day moving average price of $312.94. The company has a market capitalization of $29.64 billion, a P/E ratio of 60.44 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $239.25 and a 1-year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last announced its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The company had revenue of $1.51 billion during the quarter. On average, equities analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Jefferies Financial Group downgraded BeOne Medicines from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $420.00 to $290.00 in a report on Monday, March 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a research note on Monday, April 20th. Barclays raised their price target on shares of BeOne Medicines from $405.00 to $409.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Morgan Stanley restated an “overweight” rating and issued a $395.00 price target on shares of BeOne Medicines in a research note on Thursday, May 7th. Finally, Royal Bank Of Canada upped their price target on shares of BeOne Medicines from $425.00 to $436.00 and gave the company an “outperform” rating in a report on Tuesday, June 2nd. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $390.00.

Institutional Trading of BeOne Medicines

Institutional investors and hedge funds have recently bought and sold shares of the company. Fiera Capital Corp raised its stake in BeOne Medicines by 20.1% during the third quarter. Fiera Capital Corp now owns 25,117 shares of the company’s stock worth $8,557,000 after acquiring an additional 4,205 shares during the period. BNP Paribas Financial Markets boosted its stake in BeOne Medicines by 100.6% in the fourth quarter. BNP Paribas Financial Markets now owns 193,951 shares of the company’s stock valued at $58,924,000 after acquiring an additional 97,244 shares during the period. Slow Capital Inc. boosted its stake in BeOne Medicines by 51.5% in the fourth quarter. Slow Capital Inc. now owns 27,301 shares of the company’s stock valued at $8,294,000 after acquiring an additional 9,280 shares during the period. Generali Investments Management Co LLC bought a new position in shares of BeOne Medicines during the third quarter valued at approximately $2,726,000. Finally, Capital International Sarl grew its holdings in shares of BeOne Medicines by 2.7% during the fourth quarter. Capital International Sarl now owns 152,515 shares of the company’s stock valued at $46,336,000 after purchasing an additional 3,956 shares during the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.